New medication for atopic dermatitis safety and effectiveness
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study tests a new medication called PRA-216 for atopic dermatitis (a skin condition also known as eczema). It aims to see how safe and effective it is for people who haven't had success with topical treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with atopic dermatitis (eczema) for at least 6 months.
- Previous treatments applied to the skin (topical medications) didn't work well for you.
- You should be generally healthy with no other significant skin conditions.
- You must be able to attend all study visits and follow the study rules.
- You cannot have used other experimental treatments recently or have a history of severe allergies.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication called ARQ-234 in healthy adults and people with moderate-to-severe atopic dermatitis (eczema). The study looks at how the body handles single and multiple doses, and if it can help treat eczema.
This trial tests a new foam medication for adults with atopic dermatitis (a type of eczema). It aims to see if the foam is better than a placebo (a foam with no active ingredient) at treating the condition.
This study tests an investigational drug called PRA-216, first in healthy volunteers to check safety, then in people with mild-to-moderate asthma to see if it helps control symptoms. It's an early-stage trial to find out if the drug is safe and works.
This study tests a new medication (IBI3033) for people with moderate to severe atopic dermatitis (eczema) that hasn't responded well to creams. The goal is to see if it's safe and effective in reducing symptoms like itching and rash.
This trial tests a study drug (PF-08049820) for people with moderate to severe eczema who haven't found a suitable prescription treatment. It aims to see if the drug can improve skin symptoms and itching.
This study tests two new study medicines (PF-07275315 and PF-07264660) for people with moderate to severe eczema that hasn't responded well to other treatments, including biologics. The goal is to see if these medicines can help reduce itching and clear the skin.
Hear when a new Atopic Dermatitis (AD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.